HIGHLIGHTS
- who: BRCA and colleagues from the Department of, Radboud University Center, Nijmegen, Netherlands have published the article: Talazoparib, a Poly(ADP-ribose) Polymerase Inhibitor, for Metastatic Castration-resistant Prostate Cancer and DNA Damage Response Alterations: TALAPRO-1 Safety Analyses, in the Journal: (JOURNAL) of November/15,/2018
- what: The study demonstrated durable antitumor activity, with an objective response rate (ORR) of 29.8% (31/104; 95% CI, 21.2%-39.6%) observed for the primary cohort of patients with measurable disease. The authors provide an in-depth analysis of the Committee at each study site . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.